MicroRNAs as biomarkers and therapeutic targets in TNBC webinar

Overview

Triple negative breast cancer accounts for a disproportionate share of the total breast cancer morbidity rate due to its aggressive behavior and lack of effective targets.

Join Dr Brian Adams of Harvard Medical School as he discusses how microRNAs can serve as superior therapeutic agents in the fight against triple negative breast cancer.

Topics

miRNAs and noncoding RNA biology

Dysregulation of miRNAs associates with disease etiology

miRNAs as biomarkers

Techniques used to profile and study miRNA biology

miRNAs as therapeutic agents and/or targets

Watch now

Professional Email Address*

Country / Region*

^{^{Abcam will process your personal data in strict accordance with its privacy policy which can be found here. This will include sending you updates about Abcam, our products, and resources we think would be of interest to you. You can unsubscribe and manage your marketing preferences by clicking the link at the bottom of every email we send.}}

Meet our presenter

Meet our presenter

Brian D. Adams, PhD

Brian D. Adams, PhD is currently an Instructor at Harvard Medical School in the lab of Dr Frank Slack working to elucidate the role of microRNAs (miRNAs) in TNBC, to develop miR-34a as a therapeutic agent, and to establish a miRNA biomarker profile that associates with overall outcome and drug response in TNBC patients. Brian has over 9 years of experience in the fields of microRNA and cancer research.